Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Mouse (Murine) Anticorps:
anti-Rat (Rattus) Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Chicken Monoclonal SREBF2 Primary Antibody pour ELISA, GS - ABIN4355936
Janowski, Shan, Russell: The hypocholesterolemic agent LY295427 reverses suppression of sterol regulatory element-binding protein processing mediated by oxysterols. dans The Journal of biological chemistry 2001
Show all 14 Pubmed References
Human Polyclonal SREBF2 Primary Antibody pour ICC, IF - ABIN261631
Huster, Purnat, Burkhead, Ralle, Fiehn, Stuckert, Olson, Teupser, Lutsenko: High copper selectively alters lipid metabolism and cell cycle machinery in the mouse model of Wilson disease. dans The Journal of biological chemistry 2007
Show all 9 Pubmed References
Human Monoclonal SREBF2 Primary Antibody pour ChIP, WB - ABIN2668815
Daniëls, Smans, Royaux, Chypre, Swinnen, Zaidi: Cancer cells differentially activate and thrive on de novo lipid synthesis pathways in a low-lipid environment. dans PLoS ONE 2014
Show all 2 Pubmed References
Human Polyclonal SREBF2 Primary Antibody pour IP, WB - ABIN4355938
Karanth, Tran, Kuberan, Schlegel: Polyunsaturated fatty acyl-coenzyme As are inhibitors of cholesterol biosynthesis in zebrafish and mice. dans Disease models & mechanisms 2013
Human Polyclonal SREBF2 Primary Antibody pour ICC, IF - ABIN4355940
Mast, Lin, Anderson, Bjorkhem, Pikuleva: Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1). dans PLoS ONE 2017
MicroRNA-98 regulates hepatic cholesterol metabolism by targeting SREBP2
Hexacosanol activates AMPK and hepatic autophagy and inhibits SREBP2, resulting in hypocholesterolemic activities and improvement of hepatic steatosis.
increase in SREBP-2 directly activates expression of patatin-like phospholipase domain-containing enzyme 8 (PNPLA8) gene, and PNPLA8 associates with autophagosomes and is associated with a decrease in cellular triglyceride
Reexpression of SCAP in SCAP-deficient cells restored SREBP2 protein expression and partially restored steroidogenic responses, confirming the requirement of SCAP-SREBP2 in steroidogenesis.
The deletion of Srebf-2 and subsequent lower sterol synthesis in hepatocytes eliminated the production of an endogenous sterol ligand required for LXR activity and SREBP-1c expression.
Data, including data from studies using transgenic mice, suggest that oligodendroglial myelination requires astrocyte-derived lipids; oligodendrocyte-specific inactivation of sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP), an essential factor in lipid biosynthesis along with SREBP2, results in significantly retarded CNS myelination.
The findings suggest that Cyp3a deficiency stimulated the expression of Scap via activation of the AR, which elevated cholesterogenic gene expression levels through activation of SREBP2 and increased total cholesterol contents in the prostate.
SIRT1 gene knock-out may aggravate cartilage degeneration in osteoarthritis by activating the SREBP2 protein-mediated PI3K/AKT signalling pathway, suggesting that SIRT1 gene may play a protective role against osteoarthritis.
SREBP-2 is critical for survival and limb patterning during development
Identify a novel signaling pathway in hepatocytes triggered by ligand-activated p75NTR that via p38 MAPK and caspase-3 mediate the activation of SREBP2. This pathway may regulate LDLRs and lipid uptake particularly after injury or during tissue inflammation accompanied by an increased production of growth factors, including NGF and pro-NGF.
mTORC1/SREBP pathway is a major mechanism through which common oncogenic signaling events induce de novo lipid synthesis to promote aberrant growth and proliferation of cancer cells
This study reveals SHP as a global transcriptional partner of SREBP-2 in regulation of sterol biosynthetic gene networks and provides a potential mechanism for cholesterol-lowering action of FGF19.
activation of the sterol regulatory element binding protein-2 (SREBP2) was found to be downstream of ER stress, and this activation was affirmed to account for the intracellular accumulation of cholesterol using RNAi technique
ITCH modulates SIRT6 and SREBP2 to influence lipid metabolism and atherosclerosis in ApoE null mice
SREBP2-induced miR-92a targets key molecules in endothelial homeostasis, including sirtuin 1, Kruppel-like factor 2, and Kruppel-like factor 4, leading to NOD-like receptor family pyrin domain-containing 3 inflammasome activation and endothelial nitric oxide synthase inhibition.
The cholesterol-lowering effects of FGF21 are abrogated by hepatic expression of sterol regulatory element-binding protein-2.
Data indicate that Leishmania exploits macrophage cholesterol-dependent sterol regulatory element binding factor 2 (SREBP2) circuit to facilitate its entry and survival within the host.
Demonstrate that the activation of FXR uncouples the expression of nuclear SREBP-2 and miR-33, and the regulation of their respective target genes.
the cardiac sterol regulatory element-binding protein-2/3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway being upregulated in MMP-2 deficiency.
activation of intestinal SREBP2 alone seems to be sufficient to increase plasma cholesterol
Thus, it is evident that sauchinone reduces hepatic steatosis by downregulating the expression of hepatic PCSK9 via SREBP-2.
SREBP-2 plays a critical role in regulating osteoclastogenesis and contributes to breast cancer-induced osteolysis. Thus, SREBP-2 inhibition is a potential therapeutic approach for breast cancer patients with osteolytic bone lesions.
Our study reveals that, in addition to controlling cholesterol biosynthesis, SCAP-SREBP2 also serves as a signaling hub integrating cholesterol metabolism with inflammation in macrophages.
Data indicate a general mechanism centered on Lipin-1 and SREBP that links the physical cell microenvironment to a key metabolic pathway.
RNAi of SREBP2 in A2780 cell line resulted in a decrease of cell viability after cisplatin treatment.
SREBF2 polymorphism rs2269657 showed significant dual associations with LOAD pathological biomarkers and gene expression levels. Furthermore, SREBF2 expression levels measured in LOAD frontal cortices inversely correlated with age at death; suggesting a possible influence on survival rate.
SREBP-2 regulates autophagy-related gene expression in human liver cells.
High SREBP-2 expression is associated with hypercholesterolemia.
By altering the membrane trafficking through the lysosomes, cholesterol redistributes and regulates SREBP-2.
The gene polymorphism of SREBP2 not only significantly associated with the clinical phenotypes of osteonecrosis of the femoral head but also closely related to lipid metabolism disorder.
The current investigation indicated that the rs2267439C/T polymorphism in the SREBF-2 gene increased the T2D susceptibility in an Iranian population.
CpG sites located in SREBF2 gene showed differential methylation in association with total cholesterol. The expression of the SREBF2 was inversely associated with methylation of its corresponding CpGs.
Acidic pH-responsive SREBP2 target genes were associated with reduced overall survival of cancer patients.
these clinical and experimental results reveal a novel role of SREBP-2 in the induction of a stem cell-like phenotype and prostate cancer metastasis
These results seem to suggest an involvement of SREBF-2 in the integrity of white matter tracts in bipolar disorder and therefore a possible role of SREBP pathway in CNS myelination processes.
Date indicate that sterol regulatory element-binding proteins Srebp1 and Srebp2 are essential for the metabolic reprogramming of NK cells and for the attainment of elevated glycolysis and oxidative phosphorylation.
SREBP-1 and SREBP-2 mRNA expression levels were measured in EAT from 49 patients with CAD (26 with diabetes) and 23 controls without CAD or diabetes.SREBP expression was associated as cardiovascular risk factor for the severity of CAD and the poor lipid control.
High expression of SREBF2 is associated with high carotid intima-media thickness.
dysregulation of SIRT1-AMPK-SREBP and stimulation of NLRP3 inflammasome may contribute to vascular lipid deposition and inflammation in atherosclerosis
KLF13 and SREBP-Sp1 activation interact to regulate low density lipoprotein receptor promoter function
This gene encodes a ubiquitously expressed transcription factor that controls cholesterol homeostasis by stimulating transcription of sterol-regulated genes. The encoded protein contains a basic helix-loop-helix-leucine zipper (bHLH-Zip) domain.
sterol regulatory element binding transcription factor 2
, sterol regulatory element-binding protein 2-like
, sterol regulatory element binding protein 2
, sterol regulatory element-binding protein 2
, sterol regulatory element-binding transcription factor 2
, class D basic helix-loop-helix protein 2
, sterol regulatory element binding factor 2